This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


User:Ivan E. Wang/Sandbox 1

From Proteopedia

Jump to: navigation, search

Contents

Introduction to the RPE65

Figure 1: Emixustat and palmitate bound in the active site of RPE65

Drag the structure with the mouse to rotate

Structure and Activity

Structural Analysis of RPE65

(PLACEHOLDER)

Enzymatic Activity of RPE65

(PLACEHOLDER)

Figure 2: The canonical Visual Cycle in Humans
Figure 2: The canonical Visual Cycle in Humans [1]


Protein-Ligand Interaction

Endogenous Ligand

(PLACEHOLDER)

Exogenous Ligand

(R)-Emixustat (ACU-4429)

Figure 3:(R)-emixustat and palmitate bound in the active site of RPE65

Drag the structure with the mouse to rotate

(S)-Emixustat

Figure 4:(S)-emixustat and palmitate bound in the active site of RPE65

Drag the structure with the mouse to rotate

R/S Enantiomers Differences

(PLACEHOLDER)

Disease Implications

(PLACEHOLDER)

Medical Relevance

(PLACEHOLDER)

This is a sample scene created with SAT to by Group, and another to make of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

(PLACEHOLDER) Media:PymolRPE65.ogg

References

  1. ↑ Shin Y, Moiseyev G, Petrukhin K, Cioffi CL, Muthuraman P, Takahashi Y, Ma JX. A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration. Biochim Biophys Acta Mol Basis Dis. 2018 Jul;1864(7):2420-2429. doi:, 10.1016/j.bbadis.2018.04.014. Epub 2018 Apr 21. PMID:29684583 doi:http://dx.doi.org/10.1016/j.bbadis.2018.04.014

Proteopedia Page Contributors and Editors (what is this?)

Ivan E. Wang

Retrieved from "http://52.214.119.220/wiki/index.php/User:Ivan_E._Wang/Sandbox_1"
Personal tools